Cellular Modulators of the NRF2/KEAP1 Signaling Pathway in Prostate Cancer

Prostate cancer is the second most common malignancy in men worldwide. Prostate cancer can be treated by surgery, radiotherapy and hormone therapy. The latter, in the form of androgen-deprivation therapy is needed to reduce prostate cancer progression at an advanced stage. Several studies demonstrated that oxidative stress is involved in cancer occurrence, development and progression and the Nuclear factor erythroid 2-related factor 2 (NRF2)/Kelch Like ECH Associated Protein 1 (KEAP1) pathway is affected by reactive oxygen species (ROS). Furthermore, the NRF2/KEAP1 signaling pathway has been investigated by several studies related to anti-androgen therapy, biochemical recurrence and radiotherapy. In this review we analysed the current literature regarding the indirect modulators involved in NRF2/KEAP1 pathway regulation and their role as possible therapeutic targets in prostate cancer cells.

Automated summary

Prostate cancer is the second most common malignancy in men worldwide, and can be treated through surgery, radiotherapy and hormone therapy. Oxidative stress is involved in cancer occurrence and development, and the NRF2/KEAP1 pathway is affected by reactive oxygen species. This review analyzes the current literature on NRF2/KEAP1 pathway regulation and its potential as a therapeutic target in prostate cancer cells.